论文部分内容阅读
目的:分析探究吡柔比星在原发性局部晚期乳腺癌介入治疗上的具体效果。方法:选取我院2012年4月~2013年4月入院治疗的60例原发性局部晚期乳腺癌患者,随机将其分成治疗组与观察组,治疗组使用吡柔比星介入化疗,观察组使用术前全身静脉化疗。结果:治疗组的临床有效率以及稳定率均在观察组之上,两组患者的治疗差异显著,具有统计学意义。结论:吡柔比星术前介入化疗治疗原发性局部晚期乳腺癌,近期取得了较好的治疗效果,提升手术切除的成功率,能够最大限度的减少不良反应出现的概率,提升患者的生活质量。
Objective: To investigate the specific effect of pirarubicin on the interventional treatment of primary locally advanced breast cancer. Methods: Sixty patients with primary locally advanced breast cancer admitted to our hospital from April 2012 to April 2013 were randomly divided into treatment group and observation group. The treatment group was treated with pirarubicin and the observation group Preoperative systemic vein chemotherapy. Results: The clinical effective rate and the stability rate of the treatment group were all above the observation group. The treatment difference between the two groups was significant and statistically significant. Conclusion: Pirarubicin preoperative interventional chemotherapy in the treatment of primary locally advanced breast cancer has achieved good therapeutic effect in the near future, improving the success rate of surgical resection, minimizing the occurrence of adverse reactions and increasing the life of patients quality.